In the first three quarters, the R&D expenditure of many pharmaceutical companies increased significantly, and the innovation results were fruitful

【Pharmaceutical Network Industry News】With the successive disclosure of the third quarterly reports of listed companies in 2022, the R&D expenses of various pharmaceutical companies have also been released
.
From the perspective of pharmaceutical companies that have disclosed R&D expenditure data, in the first three quarters, many pharmaceutical companies have increased their R&D expenditure investment significantly, and the innovation results have been fruitful
.
For example, Chinese medicine company Yiling Pharmaceutical released its third quarterly report on the evening of October 27, in the first three quarters, the company's R&D expenses were 552 million yuan, and the R&D expense rate increased by 2.
6%
year-on-year.
Through continuous high R&D investment, Yiling Pharmaceutical has also accelerated the transformation of
traditional Chinese medicine achievements.
At present, the company has developed 13 innovative patented traditional Chinese medicines, covering the treatment of
cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary diseases and other diseases.
Guang'an Tang, which incurred large losses in the first three quarters, was mainly due to surging research and development expenses
.
According to the third quarterly report, the company's cumulative R&D expenses in the first three quarters increased significantly to 120 million yuan, a year-on-year increase of 169.
27%, and the proportion of operating income reached 40.
39%.

With high R&D investment, the company's innovative drug research and development progress is gratifying
.
At present, the company has developed a new target anti-hepatitis B virus new drug GST-HG121, high-activity + highly selective oral 3CL protease inhibitor GST-HG171, new c-Met targeted drug GST-HG161, non-alcoholic steatohepatitis and liver fibrosis treatment new drug GST-HG151, hepatitis B treatment innovative drug GST-HG141, GST-HG131 and other six global first-class innovative drugs have all been approved for clinical trials.
Phase I clinical studies have been carried out and a number of breakthroughs and milestones have been achieved
.
Zhongguancun is also accelerating the pace of pharmaceutical innovation, showing that the company's R&D expenditure in the first three quarters was 80.
7549 million yuan, a year-on-year increase of 82.
05%, mainly used for R&D projects
of subsidiaries in the field of biomedicine.
Under the high R&D investment, the company has begun to show results, among which the core strategic product Benidipine hydrochloride tablets have made frequent breakthroughs in the first three quarters
of this year.
Benidipine hydrochloride tablets are mainly used for the treatment of essential hypertension and angina pectoris, and are currently the first calcium antagonists
in China with both membrane penetration and three-channel block mechanisms.
The company announced on the evening of October 10 that recently, the consistency evaluation application of Shandong Huasu hydrochloride tablets (specifications: 4mg, 2mg) of Shandong Huasu, a wholly-owned subsidiary of Beijing Huasu Pharmaceutical Co.
, Ltd.
, the company's holding company, was accepted
by the State Food and Drug Administration.
For example, gene therapy CRO companies and Metabiologics reported that in the first three quarters, the company's R&D investment was 23.
7468 million yuan, an increase of 58.
94%
over the same period of the previous year.
R&D investment accounted for 11.
03% of operating income, an increase of 1.
92 percentage points over the same period last year; the R&D expenditure of vaccine company Kangtai Biologics in the first three quarters was 581 million yuan, compared with 222 million yuan in the same period last year, a year-on-year increase of 161.
34%.

The importance attached by pharmaceutical companies to R&D and innovation shows the firmness
of domestic pharmaceutical companies to take the road of innovation and sustainable development.
In January 2022, the "14th Five-Year Plan" for the development of the pharmaceutical industry was officially released, which pointed out that during the "13th Five-Year Plan" period, a large number of traditional pharmaceutical companies accelerated innovation and transformation, the number of innovative and entrepreneurial enterprises increased significantly, and the number of new drugs entering the clinical stage and R&D investment increased significantly.
During the "14th Five-Year Plan" period, a large number of pharmaceutical innovation achievements will complete clinical research and application for listing, and the pharmaceutical industry will continue to increase innovation investment and accelerate innovation-driven transformation, and by 2025, the proportion of new sales of innovative products in the industry's operating income will further increase; In March, China emphasized the key work
of continuing to promote the innovative development of the pharmaceutical industry and the efficient use of medical insurance funds.
Analysts believe that with the continuous growth of R&D investment of domestic pharmaceutical enterprises, the layout of technology research and development will be accelerated, the core competitiveness of the domestic pharmaceutical industry will continue to increase, and the follow-up development space will be broader
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.